Key result
Percutaneous hemodynamic support using Impella devices during ventricular tachycardia ablation is associated with pigment nephropathy.
Case Report
Highlights a potential complication (pigment nephropathy) associated with the use of percutaneous hemodynamic support during ventricular tachycardia ablation.
May support Impella feasibility in VT ablation; leaves open need for prospective safety and efficacy data.
The Impella mechanical assist devices (Abiomed Inc, Danvers, MA) are percutaneously inserted left ventricular assist devices developed to provide temporary circulatory support in patients in cardiogenic shock after myocardial infarction and during high-risk percutaneous coronary interventions.1,2 These devices are increasingly used in the treatment of ventricular tachycardia (VT) storm and for mechanical support during VT ablation.3–5 Induction of VT during ablation, fluid administration for catheter irrigation, and anesthesia use may lead to decompensated heart failure and worsen procedural outcomes.
No takes yet. Share an insight, caveat, or question.
Payne et al. (2020) conducted a case report in Ventricular tachycardia. Percutaneous hemodynamic support (Impella) was evaluated. Percutaneous hemodynamic support using Impella devices during ventricular tachycardia ablation is associated with pigment nephropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: